Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Omalizumab
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
'''Omalizumab''' which is sold under the brand name '''Xolair''' is a medication originally designed to reduce sensitivity to allergens and is used for treating chronic idiopathic [[urticaria]], and allergic [[asthma]].<ref name="OmalizumabSP"/><ref name="drugscom">{{Cite web | title = Omalizumab|url=https://www.drugs.com/omalizumab.html | date = Feb 20, 2022 | website = drugs.com|access-date=2022-04-05}}</ref> Omalizumab acts as a mast cell stabilizer, so it is also a potential treatment for [[Mast cell activation syndrome|mast cell disorders]].<ref name="OmalizumabSP">{{Cite book | title = Omalizumab | date = Feb 20, 2022|publisher=StatPearls Publishing|location=Treasure Island (FL) | first = Calvin | last = Kumar | first2 = Patrick M. | last2 = Zito|url=https://www.ncbi.nlm.nih.gov/books/NBK545183/|access-date=2022-04-05}}</ref><ref name="News2019">{{Cite web|url=https://www.aaaai.org/Tools-for-the-Public/Latest-Research-Summaries/The-Journal-of-Allergy-and-Clinical-Immunology-In/2019/mast-cells | title = A new therapy to calm down mast cells | last = | first = | authorlink = | date = April 9, 2019 | website = American Academy of Allergy, Asthma & Immunology|archive-url=|archive-date=|url-status=|access-date=Jul 28, 2019}}</ref> == Theory == Omalizumab is classed as a monoclonal antibody that binds to free [[immunoglobulin E]] (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing [[B cell]]s. It inhibits the binding of IgE to FcεRI on [[mast cell]]s and [[basophil]]s by binding to an antigenic epitope on IgE that overlaps with the site to which FcεRI binds. In this sense, it is a potent [[:Category:Mast cell stabilizers|mast cell stabilizer]]. == Evidence == In a study of 55 French patients with mast cell disorders treated with omalizumab, 43 patients achieved a "best response" and 76.7% of the responding patients achieved a persistent response (three months or longer.)<ref name="AAAAI-MCAS">{{Cite web|url=https://www.aaaai.org/conditions-treatments/related-conditions/mcas | title = Mast Cell Activation Syndrome (MCAS) | last = | first = | authorlink = | date = |website=American Academy of Allergy, Asthma & Immunology|archive-url=|archive-date=|url-status=|access-date=Apr 5, 2022}}</ref> Median time to first response was 2 months and median time to best response was 6 months. One severe adverse event occurred, with researchers suggesting this recommends initiating treatment in hospital, but otherwise found the safety profile acceptable.<ref name="News2019" /> ==Clinicians== ==Risks and safety== ==Costs and availability== ==See also== *[[Mast cell activation syndrome]] ==Learn more== *2019, [https://www.aaaai.org/Tools-for-the-Public/Latest-Research-Summaries/The-Journal-of-Allergy-and-Clinical-Immunology-In/2019/mast-cells A new therapy to calm down mast cells] - American Academy of Allergy, Asthma & Immunology *[https://www.drugs.com/omalizumab.html Omalizumab] - drugs.com ==References== {{Reflist}} [[Category:Potential treatments]] [[Category:Mast cell stabilizers]] [[Category:Antibodies]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Templates used on this page:
Template:Cite book
(
edit
)
Template:Cite web
(
edit
)
Template:Main other
(
edit
)
Template:Reflist
(
edit
)
Module:Check for unknown parameters
(
edit
)
Module:Citation/CS1
(
edit
)
Module:Citation/CS1/COinS
(
edit
)
Module:Citation/CS1/Configuration
(
edit
)
Module:Citation/CS1/Date validation
(
edit
)
Module:Citation/CS1/Identifiers
(
edit
)
Module:Citation/CS1/Utilities
(
edit
)
Module:Citation/CS1/Whitelist
(
edit
)
Module:No globals
(
edit
)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs